Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile
Vir(US:VIR) Businesswire·2025-11-10 07:07临床研究结果 - 公司宣布其SOLSTICE试验第48周终点分析结果 显示每月联合用药方案在慢性丁型肝炎患者中实现稳健且持久的HDV RNA检测不到率 [1] - 联合用药方案对患有肝硬化和高基线HDV RNA水平的参与者群体也显示出效果 [1]